Avelumab is a fully human IgG1 monoclonal antibody targeting PD-L1, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It has shown the ability to enhance ADCC in various cancer cell lines that express PD-L1. This reagent is primarily applicable in research focused on chordoma and related oncological studies.
Avelumab is a fully human IgG1 monoclonal antibody targeting PD-L1, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It has shown the ability to enhance ADCC in various cancer cell lines that express PD-L1. This reagent is primarily applicable in research focused on chordoma and related oncological studies.
Product Information
Catalog Num
A18234
Molecular Weight
150 kDa
CAS Number
1537032-82-8
Isotype
Human IgG1 lambda1
Species
Human
Synonyms
Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C
Storage
Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
